# A New Drug Could Be the Beginning of the End for Sleeping Sickness
For decades, sleeping sickness has devastated communities across sub-Saharan Africa, claiming hundreds of thousands of lives and leaving countless others suffering from a disease that flips their sleep cycles upside down. But a breakthrough approval by European drug regulators in February 2026 signals that the end of this ancient scourge may finally be in sight. A new pill called **acoziborole**, developed collaboratively by Sanofi and the Drugs for Neglected Diseases initiative (DNDi), represents a revolutionary shift in how we treat one of Africa’s most persistent health challenges.[1][2]
## From Arsenic to Hope
The history of sleeping sickness treatment is a sobering reminder of medical progress. In the past, doctors relied on horrifying options, including drugs containing arsenic that could actually kill patients in their attempts to cure the disease.[1] While treatments improved in the early 2000s, they remained complex and burdensome. Current regimens can take up to 10 days and require patients from remote villages to make arduous trips to hospitals.[2] Many patients have had to endure spinal taps—a procedure that helps doctors determine the infection stage and which drugs to use—adding physical trauma to an already devastating illness.[2]
Acoziborole changes everything. The new treatment is a **single-dose pill** that patients take once and are cured for all stages of the disease.[1] No hospitalization required. No complex logistics. No arsenic. For people living in remote areas of sub-Saharan Africa, where sleeping sickness predominantly strikes, this simplicity could mean the difference between life and death.
## The Disease That Poverty Enables
Sleeping sickness is fundamentally a disease of poverty. It spreads through the bite of tsetse flies, which are found only in rural, sub-Saharan Africa.[2] The infection begins innocuously, with vague flu-like symptoms, but then progressively worsens as parasites multiply and spread throughout the body, eventually reaching the nervous system.[2] The result is the disease’s namesake symptom: a reversed sleep cycle where patients are awake at night but drowsy during the day. Without treatment, coma and death inevitably follow.[2]
One reason a vaccine has never been developed is the parasite’s remarkable ability to alter its protein coat, making it nearly impossible for the immune system to mount a lasting defense.[2] This biological cunning has kept sleeping sickness off the radar of traditional pharmaceutical research and development, which typically focuses on diseases with larger, more profitable markets. That’s where organizations like DNDi come in—filling the gap left by a system driven primarily by profit rather than patient need.
## A Disease on the Brink
The good news is that sleeping sickness has already been pushed to the edge of elimination through decades of effort. Cases surged during the political and economic instability of the 1970s and 1990s, but improved treatments in the early 2000s sparked a dramatic decline.[2] By 2009, reported infections had dropped below 10,000 for the first time in fifty years.[2] Today, fewer than 600 cases of the most common form are officially reported annually, though the true number of undiagnosed infections remains unknown.[2]
The World Health Organization has set an ambitious goal: stop the spread of the most common form of sleeping sickness by 2030.[2] Acoziborole could be the tool that makes this goal achievable.
## Proof of Efficacy
The approval of acoziborole wasn’t based on theoretical promise alone. A pivotal study of approximately 200 patients in Congo and Guinea demonstrated that more than 95% of treated patients were considered cured 18 months after receiving the drug.[2] This level of effectiveness, combined with the drug’s simplicity, makes it a game-changer for treatment protocols across Africa.
The medication is currently approved for people ages 12 and older and can treat both early and advanced-stage infections.[2] Clinical trials are underway in Congo to determine its safety for younger children, with the goal of eventually expanding access to the entire pediatric population.[1]
## A Path Forward
What makes this breakthrough particularly significant is the collaborative approach behind it. Sanofi, a major pharmaceutical company, partnered with DNDi, an international organization dedicated to developing treatments for neglected diseases. This partnership, supported by the World Health Organization and health ministries across affected countries, demonstrates that addressing diseases of poverty requires a different model than traditional pharmaceutical development.[1]
Sanofi has pledged to donate doses to the World Health Organization, ensuring that the drug will be free to patients.[2] Following European regulatory approval, the WHO will include acoziborole in its treatment guidelines, and individual countries will incorporate it into their national health protocols.[1]
## The Bigger Picture
If sleeping sickness is successfully eliminated through acoziborole and sustained public health efforts, it would mark a historic milestone: the first time an infectious disease has been eradicated without a vaccine.[2] While researchers like Monica Mugnier of Johns Hopkins University caution that significant questions remain—particularly about where disease-causing parasites may be hiding—the trajectory is clear.[2]
The approval of acoziborole represents more than just a new medication. It embodies a commitment to addressing diseases that disproportionately affect the world’s poorest populations. After decades of suffering, communities across sub-Saharan Africa finally have reason to believe that sleeping sickness’s days are numbered.
Original source: NPR News – A new drug could be the beginning of the end for sleeping sickness
Leave a Reply